Christoph Lengauer, a venture partner at Third Rock Ventures, said he knew two years ago when he first spoke with Aviv Regev at the Broad Institute about single cell genomics that a company had to be built around the concept. That idea is moving forward in a fully funded start-up called Celsius Therapeutics.
The Cambridge, Mass.-based company officially launched on May 15 with $65m in Series A venture capital to interrogate genomic data at the single cell level, with the goal of identifying malfunctions within cells associated with autoimmune diseases and certain cancers
